News

The TRICIA Study, a research project pairing molecular data with artificial intelligence, was awarded funding of $1.6 million this week by the Biopharmaceutical Research Consortium CQDM, the Ministère de l’Économie et de l’Innovation of the Government of Quebec, and the Canadian Cancer Society. Dr. Mark Basik of the Jewish General...
We are pleased to share an article on Precision Oncology and the Exactis PMT initiative appearing on www.personalhealthnews.ca, and printed in the April 2019 edition of Maclean’s Magazine, as part of a Mediaplanet special interest “Advancements in Cancer Care & Rare Disease” campaign. “Precision oncology is about selecting the right...
Exactis Innovation is pleased to formally announce the launch of the Exactis Innovation Investigator-Initiated Trial (IIT) Grant Competition. In alignment with the Exactis Mission to accelerate precision oncology by matching specific molecular or clinical profiles to novel treatments available through clinical trials, the Exactis IIT Grant Competition will provide $CDN...
MRM Proteomics Inc. is partnering with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most effective treatments. The novel diagnostic test will be the first...
At risk cancer patients across Canada may now be able to have their tumors molecularly profiled using next-generation sequencing (NGS) as part of a national effort to expedite enrollments in clinical trials. Led by Exactis Innovation, a non-profit organization focused on accelerating precision cancer research and access to targeted therapies, the program’s...
Since November 2015 (when the first PMT participant signed the PMT informed consent form) you have helped us expand PMT throughout Canada and have recruited nearly 1,500 participants to name only a few milestones! The graphic below outlines some of the biggest feats we’ve been able to accomplish together in...
Five major Quebec cancer treatment centres are partnering with Montreal-based Exactis Innovation to build a coordinated network to match cancer patients to clinical trials based on the characteristics of their tumour through an innovative digital registry. The “Personalize My Treatment” (PMT) digital registry addresses the challenge of recruiting and matching cancer patients who...
At an announcement made earlier today, Merck confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative. In addition, the Cancer Research Society (CRS) and the New Brunswick Health Research Foundation (NBHRF) will also contribute...
At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company’s continued commitment to the Quebec life sciences research innovation sector by announcing a $2-million grant to the Quebec – Consortium de recherche en oncologie clinique (Q-CROC).
The Quebec – Clinical Research Organization in Cancer (Q-CROC) was awarded a $9.2 million investment from the Quebec government over four years as part of the Fonds de partenariat pour un Québec innovant et en santé (FPQIS). This public-private partnership was formally announced on February 14th, 2014 by Mr. Nicolas...
1 2 3